How does Selank (Intranasal)'s half-life affect dosing?

Selank (Intranasal) has a plasma half-life of CNS effect hours, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 2-3 sprays daily for 2-4 week courses dosing at 300 mcg per spray per dose explains the typical onset timeline for scheduling and cycle endpoints.

How do I schedule Selank (Intranasal) alongside my existing stack?

Selank (Intranasal)'s schedule is built around its CNS effect hours pharmacokinetics and 2-3 sprays daily for 2-4 week courses dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

How should Selank (Intranasal) be stored and reconstituted?

Lyophilised Selank (Intranasal) stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What is the evidence base for Selank (Intranasal)?

Selank (Intranasal)'s evidence base sits at research level investigational. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What is the mechanism of action of Selank (Intranasal)?

Same Selank molecule; olfactory pathway bypasses BBB. For scheduling and cycle applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Same Selank molecule; olfactory pathway bypasses BBB. The protocol / scheduling / cycling interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Home/ Compounds/ Selank (Intranasal)

Selank (Intranasal)

Protocol

Scheduling Selank (Intranasal) alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. The standard delivery format of Selank — intranasal spray for rapid CNS access. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.

Protocol / Scheduling / Cycling Applications

Cycle LengthMulti-Peptide TimingStack SchedulingOff-TimeTapered Cycles

Key Takeaways

Scheduling lens: Selank (Intranasal)'s CNS effect hours half-life via intranasal places it in the multi-daily-dosing bucket.
Mechanism: Same Selank molecule; olfactory pathway bypasses BBB.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Same Selank molecule; olfactory pathway bypasses BBB. Schedule design for Selank (Intranasal) starts from the pharmacokinetic constraints implied by this mechanism and the published half-life. The subsections below address daily and weekly timing, cycle length and off-period planning, stack scheduling with other compounds, and travel-and-continuity considerations.

Cycle length and off-cycle planning

Standard Selank (Intranasal) cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Stack scheduling with other compounds

When Selank (Intranasal) is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Selank (Intranasal) protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Selank (Intranasal) schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Protocol / Scheduling / Cycling Applications

Travel Considerations

For travel considerations scheduling, Selank (Intranasal) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Protocol Calendar

Schedule design for Selank (Intranasal) in protocol calendar starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Weekly Timing

The most-asked scheduling question for Selank (Intranasal) in weekly timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Tapered Cycles

For tapered cycles scheduling, Selank (Intranasal) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300 mcg per spray	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180 mcg per spray	4–6 weeks initial cycle
Protocol focus	Intranasal	300 mcg per spray	2-3 sprays daily for 2-4 week courses
Maintenance phase	Intranasal	210 mcg per spray	Ongoing with periodic pauses

Dose timing for Selank (Intranasal) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Selank (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Selank (Intranasal) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Selank (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
Selank (Intranasal) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Selank (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
Selank (Intranasal) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Selank (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
Selank (Intranasal) + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Selank (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (Russia approved)

Excellent. Mild nasal irritation possible.

Lens-specific safety considerations for protocol / scheduling / cycling use of Selank (Intranasal): Excellent. Mild nasal irritation possible. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Selank in GAD

PMID 21443549

Selank (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
Selank (Intranasal)	Tuftsin-derived heptapeptide (intranasal)	CNS effect hours	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

What is the standard dosing protocol for Selank (Intranasal)?

Conventional Selank (Intranasal) dosing is 300 mcg per spray 2-3 sprays daily for 2-4 week courses via intranasal. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What route should I use for Selank (Intranasal)?

Selank (Intranasal) is delivered by intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Clinical Protocol

Start a Selank (Intranasal) Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Selank (Intranasal) and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 751 Da
Sequence length: 7 aa
Half-life: CNS effect hours
WADA: Not on prohibited list
FDA: Unapproved (Russia approved)

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Selank (Intranasal)

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised